As the armamentarium of GDMT grows with more novel therapies, such as ARNIs and SGLT2 inhibitors, and guidelines evolve rapidly to reflect these beneficial drugs, the lack of provider confidence in managing complex GDMT regimens may continue to grow and impact optimal therapy for heart failure patients. This evidence concerns the gene SLC5A2 and heart failure.